These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23252350)

  • 1. A reference pricing system for Ireland.
    Usher C; Barry M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):675-7. PubMed ID: 23252350
    [No Abstract]   [Full Text] [Related]  

  • 2. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regresses for medicine prescription: benchmark evaluations should be eliminated].
    Dryden WA
    MMW Fortschr Med; 2013 Nov; 155 Spec No 2():16. PubMed ID: 24734441
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reimbursement of generics in Croatia: should more have been done?].
    Vukusić M
    Lijec Vjesn; 2010; 132(5-6):134-43. PubMed ID: 20677618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
    Tilson L; Bennett K; Barry M
    Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
    Lessing C; Ashton T; Davis P
    Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic substitution of antiepileptic drugs.
    Sander JW; Ryvlin P; Stefan H; Booth DR; Bauer J
    Expert Rev Neurother; 2010 Dec; 10(12):1887-98. PubMed ID: 21091318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is all "skin in the game" fair game? The problem with "non-preferred" generics.
    Oster G; Fendrick AM
    Am J Manag Care; 2014 Sep; 20(9):693-5. PubMed ID: 25365744
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adjustment of antihypertensive therapy to a generic eprosartan preparation. Results of a non-interventional study].
    Nüdling S; Kahner-Gröne S; Köneke D; Marggraf K; Palissa H
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():96-101. PubMed ID: 21595153
    [No Abstract]   [Full Text] [Related]  

  • 10. Pricing and reimbursement of drugs in Ireland.
    Barry M; Tilson L; Ryan M
    Eur J Health Econ; 2004 Jun; 5(2):190-4. PubMed ID: 15452757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of introducing inpatient mandatory generic drug substitution at Ramathobodi Hospital.
    Kaojarern S; Pattanaprateep O
    J Med Assoc Thai; 2012 Apr; 95(4):519-25. PubMed ID: 22612005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic medicines in the Malaysian health care system: Opportunities and challenges.
    Wong ZY; Alrasheedy AA; Hassali MA; Saleem F
    Res Social Adm Pharm; 2016; 12(5):807-10. PubMed ID: 27157864
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of reference-pricing systems in Europe: a literature review and case studies.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland.
    Heikkilä R; Mäntyselkä P; Ahonen R
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):185-91. PubMed ID: 21254290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
    Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
    Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference based pricing for provincial drug benefit programs.
    McLaughlin PR
    Can J Cardiol; 1996 Jan; 12(1):16, 25-6. PubMed ID: 8595565
    [No Abstract]   [Full Text] [Related]  

  • 17. Medicare prescription plan, threat to AWP could impact the ESRD drug market.
    Neumann ME
    Nephrol News Issues; 2003 Jan; 17(2):16-7, 21. PubMed ID: 12629823
    [No Abstract]   [Full Text] [Related]  

  • 18. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 19. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Policies concerning pharmaceutical prices and reimbursement in Mexico, Organization for Co-operation and Economic Development. 2007].
    Moïse P; Docteur E
    Salud Publica Mex; 2008; 50 Suppl 4():S504-10. PubMed ID: 19082262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.